Pirfenidoneone

Phase 2Small molecule

Boehringer Ingelheim

Pirfenidoneone is one of 5 small molecule programs targeting Fibrosis Syndrome. It is currently in Phase 2.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Fibrosis SyndromeRecruiting

Fibrosis SyndromePhase 2

Recruiting

Competition

Competitive Landscape

4 competitors in Fibrosis Syndrome

#DrugCompanyPhaseTrials

Pravachol

KKaruna Therapeutics, Inc., a Bristol Myers Squibb company

Phase 2

1 2

Trental

VValidus Pharmaceuticals

Phase 2

1 3

Oruvail

WWyeth-Lederle Vaccines

Phase 2

1 4

Tocopherol

MM.D. Anderson Cancer Center

Phase 2

1 5

Pirfenidoneone

Boehringer Ingelheim

Phase 2

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q3 2031

Phase 2Recruiting

Fibrosis Syndrome

NCT06912763

Clinical

Trials by Indication[1]

IPF1 trial

Safety and PK Study of BIBF 1120 in Japanese Patients With IPF: Follow up Study From 1199.31(NCT01136174)

Completed· Boehringer Ingelheim logo

Boehringer Ingelheim·Phase 2·NCT01417156·20 enrolled

Fibrosis Syndrome1 trial

Reversing External-beam Radiotherapy-associated Fibrosis Syndrome: an Interventional Bayesian Adaptive Randomized-controlled Orphan Drug Platform Trial for Orodental Sequelae (Reverse-fibrose)

Recruiting·MM.D. Anderson Cancer Center·Phase 2·NCT06912763·250 enrolled

Sources

References

[1]
ClinicalTrials.gov — 2 trial records for Pirfenidoneone. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Pirfenidoneone compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Pirfenidoneone. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Boehringer Ingelheim company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 2[1]
Company: Boehringer Ingelheim

Pirfenidoneone

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q3 2031

Trials by Indication[1]

IPF1 trial

Fibrosis Syndrome1 trial

References

Drug Info

Quick Facts

Related News